Canaccord said the Q4 results for Cibus (CBUS) were generally in line with management expectations considering the expected timeline to trait commercialization. With that said, the EU Council’s advancement of final negotiations on the legislative text governing the treatment of gene- editing technologies in the EU is significant. Canaccord maintains its Buy rating and $18 price target on Cibus shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBUS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue